Author

Irene Ong

University of Wisconsin–Madison

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Bryan P. BednarziD· 3 shared Malick Bio IdrissouiD· 3 shared Ohyun KwoniD· 3 shared Reinier T. HernandeziD· 3 shared Zachary Scott MorrisiD· 3 shared Adedamola O. AdeniyiiD· 2 shared Campbell Donnelly HaaschiD· 2 shared Jamey P. WeichertiD· 2 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Bryan P. BednarzORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Optimized dosing of spatially heterogeneous radiopharmaceutical therapy reprograms poorly immunogenic tumors to enhance response to immune checkpoint blockade

Maya E. Takashima, Zachary Danaceau, Malick Bio Idrissou, Ohyun Kwon, Tracy J. Berg, Paul A. Clark, Yujuan Wang, Wonjong Jin, Adedamola O. Adeniyi, Campbell Donnelly Haasch, Michael Antonelli, Jamey Weichert, Bryan P. Bednarz, Reinier T. Hernandez, Irene Ong, Zachary Scott Morris

This study shows that optimized spatially heterogeneous radiopharmaceutical therapy enhances immune checkpoint blockade response in poorly immunogenic tumors by promoting T cell activation and infiltration.

bioRxiv · Oct 28, 2026 · PreprintCancer Biology

Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma

Amanda G. Shea, Andrew Ollendorff, Andreanna Wilke, Lei Shi, Amy K. Erbe, Israrul Haque Ansari, Malick Bio Idrissou, Ohyun Kwon, Hansel Comas Rojas, Marta Barisa, John Anderson, Jens C. Eickhoff, Irene Ong, Rebecca M. Richards, Paul M. Sondel, , Quaovi H. Sodji

This study shows that low-dose radiopharmaceutical therapy enhances the effectiveness of B7-H3 CAR T cells in treating metastatic neuroblastoma in mice.

bioRxiv · Sep 24, 2026 · PreprintCancer Biology

Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy

Maya E. Takashima, Ohyun Kwon, Zachary Ells, Vincent R. Li, Charlotte Sawicki, Rene Welch Schwartz, Shin Hye Ahn, Hyun Meredith, Malick Bio Idrissou, Tracy J. Berg, Paul A. Clark, Michael J. Lawless, Abby Besemer, Tyler Bradshaw, Scott B. Perlman, , Zachary Scott Morris

This study shows that heterogeneous radiation dose in tumors enhances anti-tumor immunity and correlates with better clinical outcomes in prostate cancer patients.

bioRxiv · Jul 30, 2026 · PreprintCancer Biology